Stockscreener 앱 받기
0.4378
0.82%
-0.0036
시장 영업 전:
.43
-0.0078
-1.78%
전일 마감가:
$0.4414
열려 있는:
$0.4314
하루 거래량:
417.75K
Relative Volume:
0.32
시가총액:
$22.53M
수익:
-
순이익/손실:
$-22.83M
주가수익비율:
-0.5542
EPS:
-0.79
순현금흐름:
$-20.87M
1주 성능:
+17.56%
1개월 성능:
-4.68%
6개월 성능:
-22.50%
1년 성능:
-77.32%
1일 변동 폭
$0.4203
$0.4408
1주일 범위
$0.353
$0.4499
52주 변동 폭
$0.3051
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2403 SIDNEY STREET, PITTSBURGH
CGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.4378 | 22.53M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com
Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia - Benzinga
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Buy” by Analysts - Defense World
Cognition Therapeutics reports promising Alzheimer’s study results By Investing.com - Investing.com South Africa
Cognition Therapeutics reports promising Alzheimer’s study results - Investing.com
Cognition Therapeutics Presents Results at AD/PD 2025 - GlobeNewswire
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - TradingView
Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial - Stock Titan
Equities Analysts Set Expectations for CGTX FY2025 Earnings - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
HC Wainwright Has Bearish Estimate for CGTX Q1 Earnings - Defense World
Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
What is HC Wainwright’s Forecast for CGTX Q1 Earnings? - Defense World
Cognition Therapeutics to Report Biomarker Results from - GlobeNewswire
Cognition Therapeutics to present Alzheimer’s study results By Investing.com - Investing.com South Africa
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Cognition to Reveal Biomarker Findings Next Week - Baystreet.ca
Cognition Therapeutics to present Alzheimer’s study results - Investing.com India
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 - The Manila Times
Cognition Therapeutics to Present Phase 2 SHINE Study Biomarker Results for Zervimesine at AD/PD 2025 Conference - Nasdaq
Game-Changing Alzheimer's Treatment: New Phase 2 Data Reveals Multiple Positive Biomarkers - Stock Titan
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $5.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics stock price target cut to $5 at H.C. Wainwright - Investing.com Canada
Cognition Therapeutics Earnings Call: Progress Amid Challenges - MSN
Chardan Capital Has Lowered Expectations for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Brookline Capital lifts Cognition Therapeutics stock to $7 target By Investing.com - Investing.com Canada
Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... By GuruFocus - Investing.com Canada
New Horizons in Lewy Body Dementia Market Exploring Future - openPR.com
Cognition Therapeutics: Navigating the Complexities of Alzheimer's and DLB Trials - AInvest
Cognition Therapeutics Advances Alzheimer’s and DLB Trials - TipRanks
Earnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net loss - Investing.com Australia
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
COGNITION THERAPEUTICS Earnings Results: $CGTX Reports Quarterly Earnings - Nasdaq
COGNITION THERAPEUTICS INC SEC 10-K Report - TradingView
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire
Lewy Body Dementia Market to Show Remarkable Growth Trends from - openPR
Alzheimer's disease Clinical and Non-Clinical Studies, Key - openPR
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Thursday - Defense World
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - The Manila Times
Cognition Therapeutics Q4 Earnings: Key Date Revealed for Crucial Neurodegenerative Treatment Updates - StockTitan
Cognition Therapeutics at Life Sciences Forum: Progress in Alzheimer’s and Lewy Body Dementia - Investing.com UK
Cognition Therapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com India
Cognition Therapeutics, Inc. Transitions to Nasdaq Capital Market Following Compliance Notification - Nasdaq
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):